Medical network - on May 10th in the new three board pharmaceutical companies have released 2016 annual report, a total of six pharmaceutical enterprise net income reached one hundred million yuan, among them, into large biological net profit most, up to 457 million yuan, accounting for more than 44% revenue; The net profit of jade star was the biggest year-on-year growth of 110.95%. 

 

 

 

One, a large organism: increase the strength to carry out conventional vaccine development, resist product structure single risk 

 

 

 

During the period of the report, the operating income of large living organisms reached 10.2.9 billion yuan, up 9.14% from a year earlier. Net profit was 457 million yuan, an increase of 0.14%. The main source of business revenue is the production and sale of rabies vaccine, which is 95.15% in 2016. The r&d investment amounted to 0.59 billion yuan, or 5.72 percent of operating income. 

 

For into large creature, once the single product structure will lead to market volatility or competitors to produce higher quality of rabies vaccine for human use, into large creatures will be lost the existing market share and sustainable business problems. Although into large biological actively developing new products research and development projects, but the vaccine development cycle is long, after the success of the product research and development, from the application for registration to the new production marketing also need a long time. During this period, there is still a risk of a single product structure. 

 

In 2016, China implemented the two-child policy in a comprehensive way, effectively expanding the market demand for the use of the brain-activated vaccine. Currently, the big creatures will push forward with the sale of the b brain vaccine, while increasing efforts to develop other conventional vaccines. Independent research and development of bivalent kidney syndrome hemorrhagic fever vaccine production approval document (Vero cell) is preparing to declare, diploid armour liver vaccine has been approved drug clinical trials, the future into biological products will gradually rich variety. 

 

The pharmaceutical industry: 7 differentiated production workshops, covering all kinds of customized production requirements 

 

 

 

Or whole pharmaceutical industry is committed to technological innovation and commercialization of global pharmaceutical process, for the international mainstream pharmaceutical companies offer innovative drug research and development production outsourcing services, the service scope mainly covers the process research and development of new drug clinical stage and the preparation, the listed drug commercialization stage of process optimization and large-scale production, to provide clients with the integration of a open technology platform. 

 

The market for medical r&d outsourcing services continues to grow, and the market has a growing demand. During the reporting period, the total pharmaceutical revenue was 16.38 billion yuan, up 29.07 percent year on year. Net profit was 436 million yuan, up 32.1 percent year on year. Driven by strong demand, corporate revenues will remain stable and fast. 

 

The competitive advantage and brand effect of the pharmaceutical industry in the CDMO industry are increasing year by year, continuing to receive service orders. As of Dec. 31, 2016, there were 130 doctoral students, 731 master's degrees and 19 patents. With a strong r&d team and continuous r&d investment, the pharmaceutical industry has developed a strong technical competitive advantage in the pharmaceutical industry. Whole pharmaceutical industry is currently the only domestic FDA drug innovation for approval of pharmaceutical research and development of customized service outsourcing enterprises, fully embodies the its strong technology research and development and production services. 

 

Or of the whole pharmaceutical industry currently has seven differential configuration of the production workshop, covering from GMP products to the GMP products, from clinical stages to commercial production of a variety of customized production requirements. 

 

Jade star biology: product sales price increases, bringing 110.95% net profit 

 

 

 

Yuxing biology is mainly engaged in r&d, production and marketing of vitamin B12 and related extension products. Main products include: feed additives, active pharmaceutical ingredients (vitamin B12, cobalt, cobalt amino, hydroxyl amine, adenosine cobalt amine), food additives, vitamin B12, a cobalt, cobalt amino, hydroxyl amine). 

 

As a leading enterprise in the industry, the state of the jade star has been developing continuously, and its operating income and profit have been increasing for three consecutive years. During the period of the report, the operating income reached 891 million yuan, up 377 million yuan from 51.4 million yuan in the same period last year, and 73.3 percent. Net profit was 229 million yuan, up 110.95 percent from 100.8 million yuan in the same period a year earlier, and the increase was attributable to the sales price of major related products. 

 

The r&d investment in 2016 was 25.49 million yuan, up 38.74 percent year on year, accounting for 2.86 percent of its revenue. As of December 31, 2016, the company has received 71 patents, including 2 patents for inventions, which provide guarantee for the future development of the company. 

 

Jade star biological core technology for the unit output than feeding products, so the unit of fermentation technology promotion is essential, raw material price fluctuations will also affect the enterprise's operating costs, in turn, affect the enterprise's profit level. Therefore, should through the research on technological innovation, increase unit output than feeding products, improve production efficiency, reduce production cost, to enhance the enterprise competitive advantage. 

 

Four, Yangtze medicine: plant hollow capsule will replace gelatin, win market share 

 

 

 

The main business of changjiang medicine is the medicinal hollow capsule. The subsidiary "Yangtze river source" is mainly engaged in the production and sale of Chinese traditional Chinese medicine and the production and sales of functions such as honeysuckle flower dew and chrysanthemum dew. The subsidiary "changjiang feng" mainly engages in wholesale sales of pharmaceuticals, health food and medical devices. 

 

During the period of the report, the operating income of cki was 966 million yuan, up 30.48 percent from the same period last year. Net profit was 181 million yuan, up 31.59 percent from the same period last year. Medical capsule revenue was 0.63 billion yuan, accounting for 6.52% of revenue. The income of Chinese traditional Chinese medicine and functional beverages was 69.77 billion yuan, accounting for 69.77 percent of revenue. Pharmaceutical wholesale income was 227 million yuan, accounting for 23.49 percent of operating income. 

 

As one of basic pharmaceutical excipients, strengthen the hollow capsule production each link quality control, and in the process of tracking, the Yangtze river will have an opportunity for medical bring more market share. Now in addition to the gelatin hollow capsule, the Yangtze river pharmaceutical plant capsule launched new products, apply to the state food and drug administration for plant approval number of the hollow capsule, the next two years the plant capsules will fully replace the gelatin hollow capsule, huge market prospects. 

 

Yangtze river pharmaceutical has seven patents, the future of the Yangtze river pharmaceutical, will form with Chinese traditional medicine industry as the core foundation, supplemented by medical capsule, plant functional beverage, medicine, modern intelligent logistics and five large pharmaceutical retail chain business domain the new pattern of displacement in hand. 

 

Ke fiping: through the development of new drug products, we will reduce the impact of financial aid on profits 

 

 

 

He ping, focus on innovation and imitation of cardiovascular field of new drugs, in the reporting period, the company main business income is 1.251 billion yuan, reduced by 5.05%, compared to the net profit of 125 million yuan, up 17.79% from a year earlier. He main products are prescription drugs, drug demand in addition to the indications of market capacity, mainly depends on the drug efficacy and doctor's cognition to the drug, so mainly through professional academic promotion mode as a way to achieve the sales target. Combining endogenous development and extension m&a, optimize the adjustment of product structure, forming its own varieties (cerebral arteries and veins, particles) and the national total generation, purchase, oxidation camphor injection forming source contribution to the company's three big profits. 

 

He ping, adhere to the management theory of r&d driven, leading technology, nearly 5 years research and development and intellectual property rights in more than 145 million yuan, until the end of 2016, the company has a patent for invention 43 items, the cumulative gain 4 items of national science and technology major projects. He ping in the sources of natural products innovation medicine has a profound accumulation, have developed a 1.1 amine drugs mesylate silver lactone B 5 classes, Chinese traditional medicine new drug widely cohosh total sterone capsules and other products, and nurture the dozens of invention patents in the field. 

 

2016, 2015, 2014 he received government subsidies of $3696.69 respectively 3696, 5554.14 ten thousand yuan, 5003 yuan, 5003.95 accounted for the current proportion of the total amount of profits were 24.99%, 39.99% and 41.60% respectively. Government subsidies constitute an important source of corporate profits, has a larger effect on the company's performance, if the government's fiscal subsidy policy change, will have a certain influence on the company's profitability. We will adjust the profit structure through new drug development, new drug agent and product integration, so as to reduce the effect of financial aid on profit. 

 

Source and pharmacy: the new park is put into use, which can meet the processing and production of major business in the next 10 years 

 

 

 

Source and the pharmaceutical industry positioning for collection of real estate planting in traditional Chinese medicine, Chinese medicine yinpian processing, production, extraction, preparations of Chinese medicine health care tea production, sales for the integration of the whole industry chain high-tech enterprises, the main business for the Chinese medicine yinpian, proprietary Chinese medicine production and sales as well as traditional Chinese medicine trade. 

 

During the period of the report, the source and pharmaceutical industry realized operating income of 11.02 billion yuan, up 51.56 percent. Net profit was 101 million yuan, up 27.27 percent from the same period last year. The main reason is that the company's new park is officially put into use, and with the increase of production capacity and the optimization of the customer group, the revenue from the business is higher than the previous year. 

 

In May 2016, the new park was officially opened. New park covers an area of 182 mu, the park early in the planning is in line with a complete coverage of yinpian processing varieties, processing technology modernization and standardization, herbal tea and fine powder of high energy, pharmaceutical logistics distribution scale, and clean the principle of low energy design and arrangement. The completed new park will meet the company's main business growth in the next 10 years. 

 

Source and the layout of the pharmacy in Chinese medicine yinpian industry upstream and downstream industry, planting, purchasing, production, quality inspection, sales, research and development business model, and 2016 Chinese medicine yinpian main business income accounted for about 94.69%. Company's products are the main raw materials of Chinese herbal medicine, Chinese herbal medicine raw materials susceptible to supply and demand, the price of natural climate and major epidemics, price fluctuations will directly influence the cost of production and operation of the company's profit. 

 

Source and the pharmaceutical industry with zhejiang university school of medicine, China pharmaceutical university, hefei tianyuan biological research institute and so on many universities and institutions, common research and development of new products and new technology, including formula particles, saffron depth development, traditional Chinese medicine (TCM) automatic production line, new processing method of research. Increasing input particle formula research and development, the year a total of more than 550 varieties of grain formula has completed research and development and has declared, is expected to use the whole industrial chain and scale effect, fast expansion formula granules market, bring new business growth point. 

 

conclusion 

 

The traditional leading companies in the pharmaceutical industry has been basic landed a-share market and overseas market, and many committed to the research and application of new technology is still belongs to the early stage, small size and profitability, such companies have emerged in the new three board, therefore, the pattern of the new three board is on behalf of the medicine industry development in the future. And each segment has its own spigot, and once the market is formed, the market position will be relatively stable. The "second eight effect" of the new three companies (the first 20 per cent of companies with 80 per cent of the new three boards) is a further explanation for the stronger market rules of the strong.